Tenaya Therapeutics IncNASDAQ:TNYA
- LAST PRICE4.3100
- TODAY'S CHANGE (%)0.0900 (2.1327%)
- Bid / Lots3.8700/ 4
- Ask / Lots4.7500/ 1
- Open / Previous Close4.2500 / 4.2200
- Day Range
- 52 Week Range
- Volume100,974
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TNYA |
|---|---|---|
| 09:32 ET | 1126 | 4.25 |
| 09:34 ET | 500 | 4.247 |
| 09:39 ET | 100 | 4.25 |
| 09:43 ET | 600 | 4.26 |
| 09:54 ET | 100 | 4.29 |
| 09:56 ET | 1168 | 4.315 |
| 10:03 ET | 200 | 4.305 |
| 10:10 ET | 725 | 4.27 |
| 10:19 ET | 370 | 4.285 |
| 10:24 ET | 883 | 4.27 |
| 10:26 ET | 100 | 4.24 |
| 10:28 ET | 350 | 4.2224 |
| 10:32 ET | 614 | 4.25 |
| 10:33 ET | 200 | 4.29 |
| 10:46 ET | 400 | 4.26 |
| 10:50 ET | 2810 | 4.32 |
| 10:53 ET | 300 | 4.35 |
| 10:57 ET | 100 | 4.36 |
| 11:06 ET | 100 | 4.35 |
| 11:09 ET | 200 | 4.33 |
| 11:11 ET | 400 | 4.3 |
| 11:15 ET | 800 | 4.3 |
| 11:27 ET | 1355 | 4.36 |
| 11:31 ET | 800 | 4.31 |
| 11:47 ET | 100 | 4.35 |
| 11:49 ET | 100 | 4.34 |
| 11:51 ET | 100 | 4.35 |
| 12:00 ET | 135 | 4.35 |
| 12:05 ET | 100 | 4.35 |
| 12:12 ET | 100 | 4.35 |
| 12:14 ET | 700 | 4.355 |
| 12:16 ET | 800 | 4.33 |
| 12:21 ET | 200 | 4.33 |
| 12:30 ET | 100 | 4.3 |
| 12:32 ET | 2152 | 4.32 |
| 12:36 ET | 449 | 4.31 |
| 12:39 ET | 313 | 4.31 |
| 12:41 ET | 400 | 4.305 |
| 12:48 ET | 100 | 4.3 |
| 12:54 ET | 1127 | 4.305 |
| 12:56 ET | 300 | 4.32 |
| 01:03 ET | 100 | 4.33 |
| 01:08 ET | 200 | 4.32 |
| 01:14 ET | 100 | 4.34 |
| 01:24 ET | 100 | 4.36 |
| 01:37 ET | 400 | 4.33 |
| 01:46 ET | 100 | 4.33 |
| 01:48 ET | 221 | 4.33 |
| 01:53 ET | 727 | 4.35 |
| 01:57 ET | 300 | 4.34 |
| 02:02 ET | 122 | 4.34 |
| 02:06 ET | 100 | 4.33 |
| 02:09 ET | 1510 | 4.3 |
| 02:29 ET | 610 | 4.31 |
| 02:31 ET | 300 | 4.3 |
| 02:44 ET | 100 | 4.32 |
| 02:51 ET | 400 | 4.32 |
| 02:54 ET | 100 | 4.325 |
| 02:56 ET | 117 | 4.325 |
| 02:58 ET | 200 | 4.33 |
| 03:00 ET | 100 | 4.33 |
| 03:07 ET | 100 | 4.33 |
| 03:09 ET | 1130 | 4.3 |
| 03:12 ET | 100 | 4.3 |
| 03:16 ET | 3659 | 4.3 |
| 03:18 ET | 100 | 4.305 |
| 03:21 ET | 689 | 4.305 |
| 03:25 ET | 600 | 4.32 |
| 03:27 ET | 200 | 4.32 |
| 03:32 ET | 300 | 4.3 |
| 03:36 ET | 136 | 4.3 |
| 03:43 ET | 123 | 4.3 |
| 03:45 ET | 225 | 4.3 |
| 03:48 ET | 120 | 4.3 |
| 03:50 ET | 200 | 4.3 |
| 03:52 ET | 1450 | 4.3 |
| 03:54 ET | 300 | 4.295 |
| 03:56 ET | 7761 | 4.3 |
| 03:57 ET | 2537 | 4.3 |
| 03:59 ET | 3265 | 4.31 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Tenaya Therapeutics Inc | 338.4M | -2.6x | --- |
Solid Biosciences Inc | 339.1M | -1.9x | --- |
Rani Therapeutics Holdings Inc | 336.8M | -5.0x | --- |
Fibrobiologics Inc | 330.8M | -11.1x | --- |
Q32 Bio Inc | 334.3M | -0.8x | --- |
Erasca Inc | 327.6M | -2.3x | --- |
Company Information
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Contact Information
- Headquarters
- 171 Oyster Point Blvd., Suite 500SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 415-865-2066
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Goeddel
- Chief Executive Officer, Secretary
- Faraz Ali
- Chief Financial and Business Officer
- Leone Patterson
- Chief Scientific Officer
- Timothy Hoey
- Chief Medical Officer
- Whittemore Tingley
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $338.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 78.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.68 |
Book Value | $2.04 |
P/E Ratio | -2.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
